<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03388099</url>
  </required_header>
  <id_info>
    <org_study_id>1706-VLC-058-EB</org_study_id>
    <nct_id>NCT03388099</nct_id>
  </id_info>
  <brief_title>Impact of Gonadotrophin REceptor Polimorphisms on the Relationship Between Serum AMH and Ovarian Response</brief_title>
  <acronym>GREPAMOR</acronym>
  <official_title>Impact of Gonadotrophin REceptor Polimorphisms on the Relationship Between Serum AMH and Ovarian Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Valenciano de Infertilidad, IVI VALENCIA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Valenciano de Infertilidad, IVI VALENCIA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of study: To compare the relationship between serum AMH and ovarian response for IVF with
      the GnRH antagonist protocol in patients who are carriers of FSH and/or LH receptor
      polymorphisms with those that are not.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Serum AMH has shown to have a high predictive capability of the ovarian response to
      stimulation for IVF. On the other hand, patients who are carriers of polymorphisms in the FSH
      and LH receptors, have shown to need higher doses of gonadotrophins for ovarian stimulation.
      The proportion of carriers has been described to be around 20% of the population.
      Nevertheless, the determination of these polymorphisms is not performed in routine practice.
      It is unknown if their presence affects to the relationship between serum AMH levels and
      ovarian response.

      This is a prospective, single center, non-interventional, cohorts study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 11, 2018</start_date>
  <completion_date type="Actual">December 18, 2019</completion_date>
  <primary_completion_date type="Actual">December 18, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gonadotrophin receptor polymorphisms and ovarian response and AMH value</measure>
    <time_frame>1 year</time_frame>
    <description>To compare the relationship between serum AMH and ovarian response for IVF with the GnRH antagonist protocol in patients who are carriers of FSH and/or LH receptor polymorphisms with those that are not.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>polymorphisms in the FSH receptor (FSHR) variant N680S</measure>
    <time_frame>1 year</time_frame>
    <description>To define the incidence of carriers of polymorphisms in the FSH receptor (FSHR) variant N680S (homozygous and heterozygous) among women undergoing ovarian stimulation for IVF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>polymorphisms in the LH receptor (LHR) variant N312S</measure>
    <time_frame>1 year</time_frame>
    <description>To define the incidence of carriers of polymorphisms in the LH receptor (LHR) variant N312S (homozygous and heterozygous) among women undergoing ovarian stimulation for IVF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Doses of gonadotrophin needed and polymorphisms</measure>
    <time_frame>1 year</time_frame>
    <description>To analyse the doses of gonadotrophins needed for stimulation on each group of patients</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">296</enrollment>
  <condition>antimüllerian Hormone and Gonadotrophin Receptor Polymorphism as Predictors of Ovarian Response</condition>
  <arm_group>
    <arm_group_label>patients with FSH/LH polymorphisms</arm_group_label>
    <description>Infertile patients will undergo an ovarian stimulation with FSH and/or hMG. Doses will be chosen according to BMI, Antral follicle count, AMH and age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients without FSH/LH polymorphisms</arm_group_label>
    <description>Infertile patients will undergo an ovarian stimulation with FSH and/or hMG. Doses will be chosen according to BMI, Antral follicle count, AMH and age.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Infertile Patients undergoing IVF treatments
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-45 years of age presenting to IVF clinic

          -  BMI of 18-35 kg/m2

          -  Having been tested for serum AMH with the Elecsys assay

          -  Being planned to undergo ovarian stimulation cycle for IVF with the GnRH antagonist
             protocol

          -  Signed written informed consent or waiver

        Exclusion Criteria:

          -  Current or past disease affecting ovaries, gonadotropin or sex steroid

          -  Current hormone therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only women will undergo an ovarian stimulation for IVF treatment</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Valencian Institute of Infertility, IVI RMA. Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 22, 2017</study_first_submitted>
  <study_first_submitted_qc>December 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2018</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gonadotrophin receptor polymorphism</keyword>
  <keyword>antimüllerian hormone</keyword>
  <keyword>ovarian response</keyword>
  <keyword>ovarian stimulation</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

